article Open AccessTop 1% cited

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

New England Journal of Medicine · 2001 · Vol. 344(11) · pp. 783–792

Dennis J. Slamon✉(University of California, Los Angeles)Brian Leyland‐Jones(McGill University)Steven ShakH. FuchsVirginia PatonAlex BajamondeThomas Fleming(University of Washington)W. Eiermann(Olgahospital)Janet Wolter(Rush University Medical Center)Mark D. Pegram(University of California, Los Angeles)José Baselga(Vall d'Hebron Hospital Universitari)Larry Norton(Memorial Sloan Kettering Cancer Center)

View via DOI Full-text PDF

Abstract

Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.

HER2/EGFR in Cancer Research Peptidase Inhibition and Analysis Monoclonal and Polyclonal Antibodies ResearchMedicineTrastuzumabEpirubicinAnthracyclineInternal medicineBreast cancerOncologyCyclophosphamideChemotherapyDoxorubicin

MeSH terms

TrastuzumabAdultAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDoxorubicinFemaleHeart DiseasesHumansMiddle AgedNeoplasm MetastasisEpirubicinSurvival Analysis

Citations

11,439

FWCI

154.82

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers